The catechol-O-methyltransferase and monoamine oxidase B polymorphisms and levodopa therapy in the Iranian patients with sporadic Parkinson's disease

• Autorzy: Torkaman-Boutorabi A. , Shahidi G. A. , Choopani S. , Rezvani M. , Pourkosary K. , Golkar M. , Zarrindast M.-R.
• Języki publikacji: EN

Abstrakty

EN

Parkinson's disease (PD) patients vary widely in their response to levodopa treatment, and this may be partially genetic in origin. Recent studies suggest that catechol-O-methyltransferase (COMT), G1947A and monoamine oxidase B (MAOB), A644G polymorphisms might influence the risk and treatment of PD. Herein, we aimed to test the possible influence of MAOB and COMT genetic polymorphisms on the effective daily dose of levodopa administered in the fifth year of treatment. We also examined the effect of COMT and MAOB haplotypes on levodopa therapy outcome. There were 31 females and 72 males of Iranian origin diagnosed with sporadic PD included into the study. The patients were divided into two groups. Group 1: patients received daily doses of levodopa below 500 mg in the fifth year of treatment. Group 2: those patients receiving daily doses exceeding 500 mg in the fifth year of treatment. MAOB and COMT polymorphism genotyping was performed by using PCR-based restriction fragment length polymorphism (RFLP) analyses. Our data show that the first group suffered less frequently from dyskinesia than patients from the second group. No statistically significant differences were found in allele frequencies and genotype distributions of the studied genes between two groups. In addition, the incidence of the specific haplotypes between the two groups did not show any difference. The present data suggest that pharmacokinetic or pharmacodynamic factors other than the investigated genetic variants of the MAOB and COMT enzymes seem to determine the response to levodopa in the Iranian PD patients.

• Wydawca: -
• Czasopismo: Acta Neurobiologiae Experimentalis
• Rocznik: 2012
• Tom: 72
• Numer: 3
• Opis fizyczny: p.272-282,ref.

Twórcy

autor

Torkaman-Boutorabi A.

• Department of Physiology and Pharmacology, Pasteur Institute of Iran, Tehran, Iran
• Department of Neuroscience, School of Advaced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran

autor

Shahidi G. A.

• Department of Neurology, Hazrat Rasool Hospital, Tehran University of Medical Sciences, Tehran, Iran

autor

Choopani S.

• Department of Physiology and Pharmacology, Pasteur Institute of Iran, Tehran, Iran

autor

Rezvani M.

• Department of Physiology and Pharmacology, Pasteur Institute of Iran, Tehran, Iran

autor

Pourkosary K.

• Department of Physiology and Pharmacology, Pasteur Institute of Iran, Tehran, Iran

autor

Golkar M.

• Department of Parasitology, Pasteur Institute of Iran, Tehran, Iran

autor

Zarrindast M.-R.

• Department of Neuroscience, School of Advaced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran

Bibliografia

• Ahlskog J E, Muenter M D (2001) Frequency of levodoparelated dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16: 448-458.
• Balciuniene J, Emilsson L, Oreland L, Pettersson U, Jazin EE (2002) Investigation of the functional effect of mono¬amine oxidase polymorphisms in human brain. Hum Genet 110: 1-7.
• Berthet A, Bezard E (2009) Dopamine receptors and L-dopa induced dyskinesia. Parkinsonism Relat Disord 4 (Suppl.): S8-12.
• Bialecka M, Drozdzik M, Klodowska-Duda G, Honczarenko K, Gawronska- Szklarz B, Opala G, Stankiewicz J (2004) The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease. Acta Neurol Scand 110: 260-266.
• Bialecka M, Klodowska-Duda G, Honczarenko K, Gawronska-Szklarz B, Opala G, Safranow K, Drozdzik M (2007) Polymorphisms of catechol-0-methyltrans- ferase (COMT), monoamine oxidase B (MAOB), N-acetyltransferase 2 (NAT2) and cytochrome P450 2D6 (CYP2D6) gene in patients with early onset of Parkinson's disease. Parkinsonism Relat Disord 13: 224-229.
• Bialecka M, Kurzawski M, Klodowska-Duda G, Opala G, Tan EK, Drozdzik M (2008) The association of func¬tional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications. Pharmacogenet Genomics 18: 815-821.
• Blanchet PJ, Allard P, Gregoire L, Tardif F, Bedard PJ (1996) Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can J Neurol Sci 23: 189-193.
• Block G, Liss C, Reines S, Irr J, Nibbelink D (1997) Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol 37: 23-27.
• Cardoso F, Jankovic J (1997) Dystonia and dyskinesia. Psychiatr Clin North Am 20: 821-838.
• Checkoway H, Franklin G M, Costa-Mallen P, Smith-Weller T, Dilley J, Swanson P D, Costa LG (1998) A genetic polymorphism of MAO-B modifies the association of cigarette smoking and Parkinson's disease. Neurology 50: 1458-1461.
• Chong DJ, Suchowersky O, Szumlanski C, Weinshilboum RM, Brant R, Campbell NR (2000) The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease. Clin Neuropharmacol 23: 143-148.
• Contin M, Martinelli P, Mochi M, Riva R, Albani F, Baruzzi A (2005) Genetic polymorphism of catechol-O-methyl- transferase and levodopa pharmacokinetic-pharmacody- namic pattern in patients with Parkinson's disease. Mov Disord 20: 734-739.
• Corvol JC, Bonnet C, Charbonnier-Beaupel F, Bonnet AM, Fievet MH, Bellanger A, Roze E, Meliksetyan G, Ben Djebara M, Hartmann A, Lacomblez L, Vrignaud C, Zahr N, Agid Y, Costentin J, Hulot JS, Vidailhet M (2011) The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized cross¬over clinical trial. Ann Neurol 69: 111-118.
• Costa-Mallen P, Kelada SN, Costa LG, Checkoway H (2005) Characterization of the in vitro transcriptional activity of polymorphic alleles of the human monoamine oxidase-B gene. Neurosci Lett 383: 171-175.
• Danil SE, Lees AJ (1993) Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm 39: 165-172.
• de Lau LM, Verbaan D, Marinus J, Heutink P, van Hilten JJ (2012) Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson's disease. Mov Disord 27: 132-135.
• Deleu D, Northway MG, Hanssens Y (2002) Clinical phar- macokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 41: 261-309.
• Espinoza S, Manago F, Leo D, Sotnikova TD, Gainetdinov RR (2012) Role of catechol-O-methyltransferase (COMT)-dependent processes in Parkinson's disease and L-DOPA treatment. CNS Neurol Disord Drug Targets 11: 251-263.
• Fahn S, Cohen G (1992) The oxidative stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 32: 804-812.
• Garpenstrand J, Ekblom K, Forslund G, Rylander L, Oreland L (2000) Platelet monoamine oxidase activity is related to MAOB intron 13 genotype. J Neural Transm 107: 523-530.
• Gilgun-Sherki Y, Djaldetti R, Melamed E, Offen D (2004) Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease. Pharmacogenomics J 4: 291-306.
• Goetz CG, Burke PF, Leurgans S, Berry-Kravis E, Blasucci LM, Raman R, Zhou L (2001) Genetic variation analysis in Parkinson's disease patients with and without halluci¬nations: case-control study. Arch Neurol 58: 209-213.
• Goudreau JL, Maraganore DM, Farrer MJ, Lesnick TG, Singleton AB, Bower JH, Hardy JA, Rocca WA (2002) Case-control study of dopamine transporter-1, monoamine oxidase-B, and catechol-O-methyl transferase polymor¬phisms in Parkinson's disease. Mov Disord 17: 1305-1311.
• Hagell P, Widner H (1999) Clinical rating of dyskinesias in Parkinson's disease: use and reliability of a new rating scale. Mov Disord 14: 448-455.
• Hely MA, Morris JGL, Reid WGJ, O'Sullivan DJ, Williamson PM, Rail D, Broe GA, Margrie S (1994) The Sydney Multicentre Study of Parkinson's disease: A randomized, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 57: 903-910.
• Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progres¬sion, and mortality. Neurology 17: 427-442.
• Hosak L (2007) Role of the COMT gene Val158Met poly¬morphism in mental disorders: A review. Eur Psychiatry 22: 276-281.
• Hsu YP, Powell JF, Sims KB, Breakefield XO (1989) Molecular genetics of monoamine oxidases. J Neurochem 53: 12-18.
• Jankovic J (2000) Complications and limitations of drug therapy for Parkinson's disease. Neurology 55 (12 Suppl 6): S2-S6.
• Jankovic J (2006) An update on the treatment of Parkinson's disease. Mt Sinai J Med 73: 682-689.
• Kaiser R, Hofer A, Grapengiesser A, Gasser T, Kupsch A, Roots I, Brockmöller J (2003) L-dopa-induced adverse effects in PD and dopamine transporter gene polymor¬phism. Neurology 60: 1750-1755.
• Kitamura Y, Kakimura J, Taniguchi T (2002) Antiparkinsonian drugs and their neuroprotective effects. Biol Pharm Bull 25: 284-290.
• Kopin I (1985) Catecholamine metabolism: basic aspects and clinical significance. Pharmacol Rev 37: 334-364.
• Kunugi H, Nanko S, Ueki A, Otsuka E, Hattori M, Hoda F, Vallada HP, Arranz MJ, Collier DA (1997) High and low activity alleles of catechol-O-methyltransferase gene: ethnic difference and possible association with Parkinson's disease. Neurosci Lett 221: 202-204.
• Kurth JH, Kurth MC, Poduslo SE, Schwankhaus JD (1993) Association of a monoamine oxidase B allele with Parkinson's disease. Ann Neurol 33: 368-372.
• Lachman HM, Papolos DF, Saito T, Yu Y, Szumlanski CL,Weinshilboum RM (1996) Human catechol-O-meth¬yltransferase pharmacogenetics: Description of a func¬tional polymorphism and its potential application to neu- ropsychiatric disorders. Pharmacogenetics 6: 243-250.
• Lee ES, Chen H, King J, Charlton C (2008) The role of 3-O- methyldopa in the side effects of L-dopa. Neurochem Res 33: 401-411.
• Lee MS, Lyoo ChH, Ulmanen I, Syvanen AC, Rinne JO (2001) Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease. Neurosci Lett 298: 131-134.
• Lin CH, Wang CL, Huang PF, Liu YW, Ke M, Xu Y,Yu CX (2009) Genetic polymorphism of catechol O-methyltransferase and pharmacokinetics of levodopa in healthy Chinese subjects. Methods Find Exp Clin Pharmacol 31: 389-395.
• Mannisto P, Ulmanen I, Lundstrom K, Taskinen J, Tenhunen J,Tilgmann C, Kaakkola S (1992) Characteristics of cat- echol-O-methyltransferase (COMT) and properties of selective COMT inhibitors. Prog Drug Res 39: 291-350.
• Marsden CD, Parkes JD (1977) Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1: 345-349.
• Miyawaki E, Lyons K, Pahwa R, Troster AI, Hubble J, Smith D, Busenbark K, McGuire D, Michalek D, Koller WC (1997) Motor complications of chronic levodopa therapy in Parkinson's disease. Clin Neuropharmacol 20: 523-530.
• Nutt JG (1990) Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 40: 340-345.
• Nutt JG (1992) Pharmacokinetics and pharmacodynamics of levodopa: clinical implications. In: Handbook of Parkinson's Disease, 2nd ed. (Koller WC, Ed.). Marcel Dekker, New York, NY.
• Olanow CW, Watts RL, Koller WC (2001) An algorithm (decision tree) for the management of Parkinson's dis¬ease: treatment guidelines. Neurology 56 (11 Suppl 5): S1-S88.
• Peppe A, Dambrosia JM, Chase TN (1993) Risk factors for motor response complications in L-dopa-treated parkinsonian patients. Adv Neurol 60: 698-702.
• Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. New Engl J Med 342: 1484-1491.
• Reilly DK, Rivera-Calimlim L,Van Dyke D (1980) Catechol- O- methyltransferase activity: a determinant of levodopa response. Clin Pharmacol Ther 2892: 278-286.
• Rivera-Calimlim L, Reilly DK (1984) Difference in erythrocyte catechol-O-methyltransferase activity between Orientals and Caucasians: difference in levodopa toler¬ance. Clin Pharmacol Ther 35: 804-809.
• Routtinen HM (1998) COMT genotypes and response to levodopa in Parkinson's disease: influence of COMT inhibition with entacapone. Mov Disord 13: 120.
• Smit N, Pavel S, Kammeyer A, Westerhof W (1990) Determination of catechol-O-methyltransferase activity in relation to melanin metabolism using high performance liquid chromatography with fluorimetric detection. Anal Biochem 190: 286-291.
• Steventon GB, Sturman SG, Heafield MTE, Waring RH, Napier J, Williams AC (1989) Platelet monoamine oxidase-B activity in Parkinson's disease. J Neural Transm Park Dis Dement Sect 4: 255-261.
• Sun B, Zhang WY, Zhao YH (2004) Association between catechol-methyltransferase gene polymorphism and preg¬nancy induced hypertension. Zhonghua Fu Chan Ke Za Zhi 39: 21-23.
• Sweet RD, McDowell FH (1975) Five years' treatment of Parkinson's disease with levodopa: Therapeutic results and survival of 100 patients. Ann Intern Med 83: 456-463.
• Wang J, Liu ZL, Chen B (2001) Association study of dop- amine D2, D3 receptor gene polymorphism with motor fluctuation in PD. Neurology 56: 1757-1759.
• Watanabe M, Harada S, Nakamura T, Ohkoshi N, Yoshizawa K, Hayashi A, Shoji S (2003) Association between cate- chol-O-methyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinson's disease. Neuropsychobiology 48: 190-193.
• Weinshilboum RM, Otterness DM, Szumlanski CL (1999) Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and his- tamine N-methyltransferase. Annu Rev Pharmacol Toxicol 39: 19-52.
• Wu RM, Cheng CW, Chen KH, Lu SL, Shan DE, Ho YF, Chern HD (2002) The COMT L allele modifies the asso¬ciation between MAOB polymorphism and PD in Taiwanese. Neurology 56: 375-82.
• Yoritaka A, Hattori N, Yoshino H, Mizuno Y (1997) Catechol-O-methyltransferase genotype and susceptibili¬ty to Parkinson's disease in Japan. Short communication. J Neural Transm 104: 1313-1317.

Uwagi

Rekord w opracowaniu